Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic b...
Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients
About this item
Full title
Author / Creator
Publisher
Firenze: Taylor & Francis
Journal title
Language
English
Formats
Publication information
Publisher
Firenze: Taylor & Francis
Subjects
More information
Scope and Contents
Contents
Background: To explore clinical outcomes and cardiac safety of continuous antiHer2 therapy.
Patients and methods: This retrospective study evaluates overall survival (OS), time to treatment failure (TTF), and cardiac safety of 80 consecutive Her2-positive metastatic breast cancer (MBC) patients that received ≧ 12 months of therapy with trastuzum...
Alternative Titles
Full title
Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pascalfrancis_primary_28083821
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pascalfrancis_primary_28083821
Other Identifiers
ISSN
1120-009X
E-ISSN
1973-9478
DOI
10.1179/1973947813Y.0000000098
